NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 1 FDA
NCT06693128 2026-01-28Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerRuijin HospitalPhase 2 Active not recruiting80 enrolled
NCT04208347 2026-01-23Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerRuijin HospitalPhase 2/3 Active not recruiting580 enrolled
NCT04864067 2025-07-01NOAHS-ARCServicio de Salud Metropolitano Sur OrientePhase 2 Active not recruiting73 enrolled
NCT02509286 2024-05-08ESOPECUniversity Hospital Schleswig-HolsteinPhase 3 Active not recruiting438 enrolled